View in EDS

Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction

Saved in:
Bibliographic Details
Title: Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction
Authors: Matthias Mezger, Tilmann Solle, Dominik Jurczyk, Caroline Fatum, Felicitas Lemmer, Ingo Eitel, Christina Paitazoglou
Source: Atheroscler Plus
Atherosclerosis Plus, Vol 61, Iss, Pp 29-34 (2025)
Publisher Information: Elsevier BV, 2025.
Publication Year: 2025
Subject Terms: Myocardial infarction, Lp(a), Heart-failure, RC666-701, Full Length Article, Diseases of the circulatory (Cardiovascular) system, Pelacarsen
Description: BACKGROUND AND AIMS: Atherosclerotic cardiovascular disease (ASCVD) is a major health burden being the leading cause of death in Europe. Lipoprotein (a) (Lp(a)) is an important risk factor for CV events reflected by the 2019 ESC recommendation of a once in a lifetime Lp(a) measurement. Furthermore, heart-failure (HF) is the number one diagnosis for hospital admission in Germany and Europe. HF and ASCVD share common well-known risk factors, e.g. diabetes, obesity and hypertension. So far, there is scarcity of data regarding the relationship between Lp(a) and HF. We hypothesized that Lp(a) might be elevated in a high-risk ASCVD patient collective and that there might also be an association with heart-failure. METHODS: The Luebeck Lp(a) HF registry is a combined retrospective/prospective single-center, all-comers registry which investigates the relationship between Lp(a) and HF. The retrospective analysis reported here, comprises patients who were admitted to our heart-catheterization laboratory in the year 2021 due to ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). RESULTS: We found that Lp(a) was assessed only in a minority of patients presenting with STEMI (33 %) and NSTEMI (14.6 %), p
Document Type: Article
Other literature type
Language: English
ISSN: 2667-0895
DOI: 10.1016/j.athplu.2025.07.002
Access URL: https://doaj.org/article/22f6c6f2822c494394d10c3c6a438b82
Rights: CC BY
Accession Number: edsair.doi.dedup.....cf64c7c8eb8fb0f4590db52f24872ffb
Database: OpenAIRE
Description
Abstract:BACKGROUND AND AIMS: Atherosclerotic cardiovascular disease (ASCVD) is a major health burden being the leading cause of death in Europe. Lipoprotein (a) (Lp(a)) is an important risk factor for CV events reflected by the 2019 ESC recommendation of a once in a lifetime Lp(a) measurement. Furthermore, heart-failure (HF) is the number one diagnosis for hospital admission in Germany and Europe. HF and ASCVD share common well-known risk factors, e.g. diabetes, obesity and hypertension. So far, there is scarcity of data regarding the relationship between Lp(a) and HF. We hypothesized that Lp(a) might be elevated in a high-risk ASCVD patient collective and that there might also be an association with heart-failure. METHODS: The Luebeck Lp(a) HF registry is a combined retrospective/prospective single-center, all-comers registry which investigates the relationship between Lp(a) and HF. The retrospective analysis reported here, comprises patients who were admitted to our heart-catheterization laboratory in the year 2021 due to ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). RESULTS: We found that Lp(a) was assessed only in a minority of patients presenting with STEMI (33 %) and NSTEMI (14.6 %), p
ISSN:26670895
DOI:10.1016/j.athplu.2025.07.002